117 related articles for article (PubMed ID: 26608003)
1. A fast and specific method to screen for intracellular amyloid inhibitors using bacterial model systems.
Navarro S; Carija A; Muñoz-Torrero D; Ventura S
Eur J Med Chem; 2016 Oct; 121():785-792. PubMed ID: 26608003
[TBL] [Abstract][Full Text] [Related]
2. Fluorescent dye ProteoStat to detect and discriminate intracellular amyloid-like aggregates in Escherichia coli.
Navarro S; Ventura S
Biotechnol J; 2014 Oct; 9(10):1259-66. PubMed ID: 25112199
[TBL] [Abstract][Full Text] [Related]
3. Using bacterial inclusion bodies to screen for amyloid aggregation inhibitors.
Villar-Piqué A; Espargaró A; Sabaté R; de Groot NS; Ventura S
Microb Cell Fact; 2012 May; 11():55. PubMed ID: 22553999
[TBL] [Abstract][Full Text] [Related]
4. Potent anticholinesterasic and neuroprotective pyranotacrines as inhibitors of beta-amyloid aggregation, oxidative stress and tau-phosphorylation for Alzheimer's disease.
García-Font N; Hayour H; Belfaitah A; Pedraz J; Moraleda I; Iriepa I; Bouraiou A; Chioua M; Marco-Contelles J; Oset-Gasque MJ
Eur J Med Chem; 2016 Aug; 118():178-92. PubMed ID: 27128182
[TBL] [Abstract][Full Text] [Related]
5. Thioflavin-S staining of bacterial inclusion bodies for the fast, simple, and inexpensive screening of amyloid aggregation inhibitors.
Pouplana S; Espargaro A; Galdeano C; Viayna E; Sola I; Ventura S; Muñoz-Torrero D; Sabate R
Curr Med Chem; 2014; 21(9):1152-9. PubMed ID: 24059241
[TBL] [Abstract][Full Text] [Related]
6. A Ligand-Based NMR Screening Approach for the Identification and Characterization of Inhibitors and Promoters of Amyloid Peptide Aggregation.
Dalvit C; Santi S; Neier R
ChemMedChem; 2017 Sep; 12(17):1458-1463. PubMed ID: 28722296
[TBL] [Abstract][Full Text] [Related]
7. Protein aggregation propensity is a crucial determinant of intracellular inclusion formation and quality control degradation.
Villar-Piqué A; Ventura S
Biochim Biophys Acta; 2013 Dec; 1833(12):2714-2724. PubMed ID: 23856334
[TBL] [Abstract][Full Text] [Related]
8. Yeast as a Model for Studies on Aβ Aggregation Toxicity in Alzheimer's Disease, Autophagic Responses, and Drug Screening.
Porzoor A; Macreadie I
Methods Mol Biol; 2016; 1303():217-26. PubMed ID: 26235069
[TBL] [Abstract][Full Text] [Related]
9. Bacterial inclusion bodies of Alzheimer's disease β-amyloid peptides can be employed to study native-like aggregation intermediate states.
Dasari M; Espargaro A; Sabate R; Lopez del Amo JM; Fink U; Grelle G; Bieschke J; Ventura S; Reif B
Chembiochem; 2011 Feb; 12(3):407-23. PubMed ID: 21290543
[TBL] [Abstract][Full Text] [Related]
10. Bacterial Inclusion Bodies for Anti-Amyloid Drug Discovery: Current and Future Screening Methods.
Caballero AB; Espargaró A; Pont C; Busquets MA; Estelrich J; Muñoz-Torrero D; Gamez P; Sabate R
Curr Protein Pept Sci; 2019; 20(6):563-576. PubMed ID: 30924417
[TBL] [Abstract][Full Text] [Related]
11. Screening Protein Aggregation in Cells Using Fluorescent Labels Coupled to Flow Cytometry.
Ventura S; Navarro S
Methods Mol Biol; 2019; 1873():195-212. PubMed ID: 30341611
[TBL] [Abstract][Full Text] [Related]
12. Divergent synthesis of biflavonoids yields novel inhibitors of the aggregation of amyloid β (1-42).
Sum TH; Sum TJ; Collins S; Galloway WRJD; Twigg DG; Hollfelder F; Spring DR
Org Biomol Chem; 2017 May; 15(21):4554-4570. PubMed ID: 28513756
[TBL] [Abstract][Full Text] [Related]
13. Flow-cytometric screening of aggregation-inhibitors using a fluorescence-assisted intracellular method.
Lindberg H; Sandersjöö L; Meister SW; Uhlén M; Löfblom J; Ståhl S
Biotechnol J; 2017 Jan; 12(1):. PubMed ID: 27860405
[TBL] [Abstract][Full Text] [Related]
14. In vivo amyloid aggregation kinetics tracked by time-lapse confocal microscopy in real-time.
Villar-Piqué A; Espargaró A; Ventura S; Sabate R
Biotechnol J; 2016 Jan; 11(1):172-7. PubMed ID: 26580000
[TBL] [Abstract][Full Text] [Related]
15. A plant cell-based system that predicts aβ42 misfolding: potential as a drug discovery tool for Alzheimer's disease.
Zhao T; Zeng Y; Kermode AR
Mol Genet Metab; 2012 Nov; 107(3):571-9. PubMed ID: 22944366
[TBL] [Abstract][Full Text] [Related]
16. Inclusion bodies: specificity in their aggregation process and amyloid-like structure.
Morell M; Bravo R; Espargaró A; Sisquella X; Avilés FX; Fernàndez-Busquets X; Ventura S
Biochim Biophys Acta; 2008 Oct; 1783(10):1815-25. PubMed ID: 18619498
[TBL] [Abstract][Full Text] [Related]
17. Anti-Amyloid Drug Screening Methods Using Bacterial Inclusion Bodies.
Caballero AB; Gamez P; Sabate R; Espargaró A
Methods Mol Biol; 2022; 2538():165-188. PubMed ID: 35951300
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity and Turnover of Intermediates during Amyloid-β (Aβ) Peptide Aggregation Studied by Fluorescence Correlation Spectroscopy.
Tiiman A; Jarvet J; Gräslund A; Vukojević V
Biochemistry; 2015 Dec; 54(49):7203-11. PubMed ID: 26574169
[TBL] [Abstract][Full Text] [Related]
19. Thioflavin-S staining coupled to flow cytometry. A screening tool to detect in vivo protein aggregation.
Espargaró A; Sabate R; Ventura S
Mol Biosyst; 2012 Nov; 8(11):2839-44. PubMed ID: 22868714
[TBL] [Abstract][Full Text] [Related]
20. Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases.
Galdeano C; Viayna E; Sola I; Formosa X; Camps P; Badia A; Clos MV; Relat J; Ratia M; Bartolini M; Mancini F; Andrisano V; Salmona M; Minguillón C; González-Muñoz GC; Rodríguez-Franco MI; Bidon-Chanal A; Luque FJ; Muñoz-Torrero D
J Med Chem; 2012 Jan; 55(2):661-9. PubMed ID: 22185619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
